Strides Pharma Science is currently trading at Rs. 417.75, up by 4.00 points or 0.97% from its previous closing of Rs. 413.75 on the BSE.
The scrip opened at Rs. 416.75 and has touched a high and low of Rs. 427.55 and Rs. 394.20 respectively. So far 321085 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 875.72 on 27-Dec-2017 and a 52 week low of Rs. 334.10 on 08-Jun-2018.
Last one week high and low of the scrip stood at Rs. 427.55 and Rs. 390.50 respectively. The current market cap of the company is Rs. 3749.86 crore.
The promoters holding in the company stood at 30.79%, while Institutions and Non-Institutions held 47.54% and 21.68% respectively.
Strides Pharma Science has executed definitive agreements with funds advised by ICP?III Investment Advisors (ICP) to provide growth capital and focused attention to its Consumer Healthcare Business (CHC).
ICP would provide the business with a $20 million capital for growth. The CHC business comprises of key brands including JointFlex, Pediacare, NiteThru and NixIt sold across key regulated and emerging markets. The business had revenues of $6.4 million for FY18.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
